Hiroki Yamaue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hiroki Yamaue has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Seiko Hirono
Department of Hepato‐Biliary‐Pancreatic Surgery Hyogo Medical University Nishinomiya Japan
28 shared publications - Manabu Kawai
Second Department of Surgery Wakayama Medical University Wakayama Japan
21 shared publications - Ken-Ichi Okada
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
19 shared publications Motoki Miyazawa
13 shared publicationsYuji Kitahata
13 shared publicationsAtsushi Shimizu
11 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB227-AB228
Sa1353 THE EFFICIENCY AND SAFETY OF ENDOSCPIC SPHINCTEROTOMY TO PREVENT POST-ERCP PANCREATITIS IN BILIARY NEOPLASM; A MULTICENTER RETROSPECTIVE COHORT STUDY
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB227-AB228
Sa1353 THE EFFICIENCY AND SAFETY OF ENDOSCPIC SPHINCTEROTOMY TO PREVENT POST-ERCP PANCREATITIS IN BILIARY NEOPLASM; A MULTICENTER RETROSPECTIVE COHORT STUDY
- 25 April 2018
- Published by Japan Pancreas Society in Suizo
- Vol. 33 (2) , 111-117
Up-to-date Surgical treatment of intraductal papillary mucinous neoplasms
- 25 April 2018
- Published by Japan Pancreas Society in Suizo
- Vol. 33 (2) , 111-117
Up-to-date Surgical treatment of intraductal papillary mucinous neoplasms
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB090
AB090. P062. Strategy of postoperative follow-up for intraductal papillary mucinous neoplasms
Background: This study aimed to evaluate the postoperative recurrence risk factors for intraductal papillary mucinous neoplasm (IPMN), and to suppose an appropriate surveillance after surgical resection. Methods: This study included 257 consecutive IPMN patients undergoing surgery from 1999 to 2014. Pathological diagnosis showed low- or intermediate-grade dysplasia in 85 patients (33.1%), high-grade dysplasia in 87 patients (33.8%), and invasive intraductal papillary mucinous carcinoma (IPMC) in 85 patients (33.1%). The median postoperative follow-up period was 53.5 months. Results: Fifty-six IPMN patients (21.8%) had recurrence after surgery, including those with remnant pancreatic recurrence (n=14) and extra-pancreatic recurrence (n=42). Remnant pancreatic recurrence had no influence on the overall survival (OS), whereas, patients with extra-pancreatic recurrence had significantly worse OS (PConclusions: Our data suggest that continuous surveillance for more than 5 years after surgery is needed for all IPMN patients to evaluate the remnant pancreatic recurrence, and strict 5-year surveillance is necessary for IPMN patients at risk for extra-pancreatic recurrence.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB090
AB090. P062. Strategy of postoperative follow-up for intraductal papillary mucinous neoplasms
Background: This study aimed to evaluate the postoperative recurrence risk factors for intraductal papillary mucinous neoplasm (IPMN), and to suppose an appropriate surveillance after surgical resection. Methods: This study included 257 consecutive IPMN patients undergoing surgery from 1999 to 2014. Pathological diagnosis showed low- or intermediate-grade dysplasia in 85 patients (33.1%), high-grade dysplasia in 87 patients (33.8%), and invasive intraductal papillary mucinous carcinoma (IPMC) in 85 patients (33.1%). The median postoperative follow-up period was 53.5 months. Results: Fifty-six IPMN patients (21.8%) had recurrence after surgery, including those with remnant pancreatic recurrence (n=14) and extra-pancreatic recurrence (n=42). Remnant pancreatic recurrence had no influence on the overall survival (OS), whereas, patients with extra-pancreatic recurrence had significantly worse OS (PConclusions: Our data suggest that continuous surveillance for more than 5 years after surgery is needed for all IPMN patients to evaluate the remnant pancreatic recurrence, and strict 5-year surveillance is necessary for IPMN patients at risk for extra-pancreatic recurrence.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB027
AB027. S027. Factors associated with invasive intraductal papillary mucinous carcinoma
Background: Invasive intraductal papillary mucinous carcinoma (IPMC) may have distant or lymph node metastasis, and postoperative recurrence may occur, leading to poor survival even after resection. To identify the specific predictors of invasive IPMC for branch duct (BD), main duct (MD), and mixed types. Methods: This study included 286 consecutive patients undergoing surgical resection for intraductal papillary mucinous neoplasm (IPMN). We compared clinical features between invasive IPMC and noninvasive IPMN for each morphological type. Results: High mural nodule size measured by endoscopic ultrasonography was an independent predictor of invasive IPMC in all types of IPMN [BD-IPMN: P=0.01, odds ratio (OR), 1.992; mixed-IPMN: P=0.042, OR, 1.178; MD-IPMN: P=0.01, OR, 1.443]. Its cutoff values, determined by a receiver operating characteristic were 9 mm in BD-IPMN and 6 mm in mixed- and MD-IPMNs. A high carcinoembryonic antigen (CEA) level in the pancreatic juice was an independent predictive factor of mixed- and MD-invasive IPMCs (mixed-IPMN: P=0.011, OR, 1.002; MD-IPMN: P=0.048, OR, 1.002), and the cutoff values were determined to be 150 and 300 ng/mL, respectively. In addition, we found that being female (P=0.014, OR, 6.135) and having elevated serum carbohydrate antigen 19-9 (P=0.009, OR, 29.412) were also independent predictors of mixed-invasive IPMC, and using any two among four identified predictors yielded the highest accuracy (79.0%). For all types, the accuracy for these predictors was 86.0% for differentiation between invasive and noninvasive IPMN. Conclusions: The measurement of mural nodule size in all types of IPMN and the CEA level in the pancreatic juice in mixed- and MD-IPMNs might play important roles in predicting invasive IPMC, but further large studies are needed to confirm these results (JAMA Surg, 2017).
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB027
AB027. S027. Factors associated with invasive intraductal papillary mucinous carcinoma
Background: Invasive intraductal papillary mucinous carcinoma (IPMC) may have distant or lymph node metastasis, and postoperative recurrence may occur, leading to poor survival even after resection. To identify the specific predictors of invasive IPMC for branch duct (BD), main duct (MD), and mixed types. Methods: This study included 286 consecutive patients undergoing surgical resection for intraductal papillary mucinous neoplasm (IPMN). We compared clinical features between invasive IPMC and noninvasive IPMN for each morphological type. Results: High mural nodule size measured by endoscopic ultrasonography was an independent predictor of invasive IPMC in all types of IPMN [BD-IPMN: P=0.01, odds ratio (OR), 1.992; mixed-IPMN: P=0.042, OR, 1.178; MD-IPMN: P=0.01, OR, 1.443]. Its cutoff values, determined by a receiver operating characteristic were 9 mm in BD-IPMN and 6 mm in mixed- and MD-IPMNs. A high carcinoembryonic antigen (CEA) level in the pancreatic juice was an independent predictive factor of mixed- and MD-invasive IPMCs (mixed-IPMN: P=0.011, OR, 1.002; MD-IPMN: P=0.048, OR, 1.002), and the cutoff values were determined to be 150 and 300 ng/mL, respectively. In addition, we found that being female (P=0.014, OR, 6.135) and having elevated serum carbohydrate antigen 19-9 (P=0.009, OR, 29.412) were also independent predictors of mixed-invasive IPMC, and using any two among four identified predictors yielded the highest accuracy (79.0%). For all types, the accuracy for these predictors was 86.0% for differentiation between invasive and noninvasive IPMN. Conclusions: The measurement of mural nodule size in all types of IPMN and the CEA level in the pancreatic juice in mixed- and MD-IPMNs might play important roles in predicting invasive IPMC, but further large studies are needed to confirm these results (JAMA Surg, 2017).
- 12 February 2018
- Published by Wiley
- p. 797-803
Total Pancreatectomy
- 1 July 2017
- Published by Elsevier in Pancreatology
- Vol. 17 (3) , S115
Multicenter single-arm, prospective study of reinforced stapler with bioabsorbable materials to prevent pancreatic fistula after distal pancreatectomy
- 1 July 2017
- Published by Elsevier in Pancreatology
- Vol. 17 (3) , S115
Multicenter single-arm, prospective study of reinforced stapler with bioabsorbable materials to prevent pancreatic fistula after distal pancreatectomy
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1239
The Efficacy of Perioperative Fluid Restriction for Postoperative Complications after Pancreatoduodenectomy
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1239
The Efficacy of Perioperative Fluid Restriction for Postoperative Complications after Pancreatoduodenectomy
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1270
Comparison of Long-Term Pancreatic Exocrine Functions of Pancreaticojejunostomy and Pancreaticogastrostomy after Pancreaticoduodenectomy: A Dual-Center Prospective Cohort Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1270
Comparison of Long-Term Pancreatic Exocrine Functions of Pancreaticojejunostomy and Pancreaticogastrostomy after Pancreaticoduodenectomy: A Dual-Center Prospective Cohort Study
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S171
Dendritic cell vaccine transduced with ubiquitin-mesothelin fusion gene for pancreatic cancer
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S171
Dendritic cell vaccine transduced with ubiquitin-mesothelin fusion gene for pancreatic cancer